The electrocompetent cells market is estimated to be valued at US$ 2.07 billion in 2023 and is expected to exhibit a CAGR of 10.5% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Electrocompetent cells are cells that have the ability to take up and express foreign DNA molecules. These cells have gained significant importance in genetic engineering and synthetic biology. They are extensively used in various applications such as cloning, protein expression, mutagenesis, and genome editing. The increasing demand for genetic engineering techniques, along with the rise in synthetic biology research, is expected to drive the growth of the electrocompetent cells market.

Key Takeaways:

The global electrocompetent cells market is expected to witness high growth, exhibiting a CAGR of 10.5% over the forecast period, due to increasing demand for genetic engineering and molecular biology research. The market is dominated by North America, owing to the presence of a well-established research infrastructure and key industry players. However, the Asia Pacific region is expected to be the fastest-growing region, driven by the rising investments in life sciences research and the increasing focus on personalized medicine. Key players operating in the electrocompetent cells market include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., and New England Biolabs, Inc.

Read More:

https://www.articledistrict.com/electrocompetent-cells-market-to-reach-us-2-07-billion-by-2023/